KR101988705B1 - 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물 - Google Patents

재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물 Download PDF

Info

Publication number
KR101988705B1
KR101988705B1 KR1020167007373A KR20167007373A KR101988705B1 KR 101988705 B1 KR101988705 B1 KR 101988705B1 KR 1020167007373 A KR1020167007373 A KR 1020167007373A KR 20167007373 A KR20167007373 A KR 20167007373A KR 101988705 B1 KR101988705 B1 KR 101988705B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
protein
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167007373A
Other languages
English (en)
Korean (ko)
Other versions
KR20160044034A (ko
Inventor
마이클 앤쏘니 얀코브스키
키쓰 에이. 존슨
웬디 캐롤 피아센자
제이슨 씨. 라우즈
마이클 샤마쉬킨
페넬로페 제인 샤프
매리 베쓰 스위처
스테이시 비. 웨스톤
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20160044034A publication Critical patent/KR20160044034A/ko
Application granted granted Critical
Publication of KR101988705B1 publication Critical patent/KR101988705B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
KR1020167007373A 2013-09-24 2014-09-16 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물 Expired - Fee Related KR101988705B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
US61/881,834 2013-09-24
PCT/IB2014/064564 WO2015044836A1 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Publications (2)

Publication Number Publication Date
KR20160044034A KR20160044034A (ko) 2016-04-22
KR101988705B1 true KR101988705B1 (ko) 2019-06-12

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167007373A Expired - Fee Related KR101988705B1 (ko) 2013-09-24 2014-09-16 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물

Country Status (19)

Country Link
US (3) US9757434B2 (https=)
EP (1) EP3049434A1 (https=)
JP (1) JP6429885B2 (https=)
KR (1) KR101988705B1 (https=)
CN (2) CN112195169A (https=)
AR (1) AR097732A1 (https=)
AU (1) AU2014326257B2 (https=)
BR (1) BR112016005899A8 (https=)
CA (1) CA2924981C (https=)
HK (1) HK1218760A1 (https=)
IL (2) IL244258A0 (https=)
MX (1) MX373466B (https=)
MY (1) MY173548A (https=)
PE (1) PE20160877A1 (https=)
RU (1) RU2648144C2 (https=)
SA (1) SA516370751B1 (https=)
SG (1) SG11201601221XA (https=)
TW (1) TWI631134B (https=)
WO (1) WO2015044836A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175931A1 (en) 2005-11-15 2009-07-09 Camire Rodney M Compositions and methods for modulating hemostasis
WO2013049804A1 (en) 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
MX2011004907A (es) * 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
TW201217527A (en) * 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3063170A4 (en) 2013-11-01 2017-06-28 The Children's Hospital of Philadelphia Compositions and methods for increasing the half-life of factor xa
BR112016014617A2 (pt) 2014-01-24 2017-09-19 Pfizer Variante do fator xa (fxa) e usos da referida variante

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175931A1 (en) 2005-11-15 2009-07-09 Camire Rodney M Compositions and methods for modulating hemostasis
WO2013049804A1 (en) 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature Biotechnology, Vol.29, No. 11, pp1028-1033, (2011 October).

Also Published As

Publication number Publication date
RU2016108608A (ru) 2017-10-26
JP6429885B2 (ja) 2018-11-28
WO2015044836A1 (en) 2015-04-02
KR20160044034A (ko) 2016-04-22
US20210106658A1 (en) 2021-04-15
BR112016005899A8 (pt) 2018-02-06
AU2014326257A1 (en) 2016-03-10
TWI631134B (zh) 2018-08-01
MY173548A (en) 2020-02-04
SA516370751B1 (ar) 2018-04-05
US20150182604A1 (en) 2015-07-02
IL279396A (en) 2021-01-31
MX373466B (es) 2020-05-25
TW201524996A (zh) 2015-07-01
HK1218760A1 (zh) 2017-03-10
PE20160877A1 (es) 2016-09-11
US10660946B2 (en) 2020-05-26
US9757434B2 (en) 2017-09-12
CN105579468A (zh) 2016-05-11
EP3049434A1 (en) 2016-08-03
US20170333535A1 (en) 2017-11-23
MX2016003871A (es) 2016-08-04
SG11201601221XA (en) 2016-04-28
CN112195169A (zh) 2021-01-08
BR112016005899A2 (pt) 2017-09-26
JP2016535071A (ja) 2016-11-10
RU2648144C2 (ru) 2018-03-22
AU2014326257B2 (en) 2017-08-10
CA2924981A1 (en) 2015-04-02
IL244258A0 (en) 2016-04-21
AR097732A1 (es) 2016-04-13
CA2924981C (en) 2020-03-31

Similar Documents

Publication Publication Date Title
US20210106658A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
US9388402B2 (en) Method for improved isolation of recombinantly produced proteins
US20250230426A1 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
NO321096B1 (no) Fremgangsmate for forbedring av in vivo-funksjonen av rekombinant faktor VIII SQ ved a skjerme utsatte mal pa polypeptidet
KR20110005862A (ko) 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
NO339740B1 (no) Eukaryot vertscelle som omfatter minst en ekspresjonsvektor, nevnte vektor omfattende et nukleinsyremolekyl, metode for å produsere gamma-karboksylert protein samt metode for å produsere farmasøytisk preparat basert på samme
KR20120118028A (ko) 혈액 응고 인자의 정제
TW202346582A (zh) 一種凝血因子ｘ啟動酶及其應用
CN103814137A (zh) 处理凝血因子的方法
AU2014202989B2 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
KR20190003742A (ko) 인자 ｘ 변이체
KR101486835B1 (ko) 고순도 가용성 트롬보모듈린 및 그 제조 방법
HK40007078A (en) Method for isolation of recombinantly produced proteins
WO2017025566A1 (en) Improved recombinant factor vii
HK1178048A (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
AU2016238889A1 (en) Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
HK1151184A1 (zh) 重组纤维蛋白原

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220606

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220606

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000